Apabetalone and Alkaline Phosphatase Data Highlighted in Multiple Presentations
TSX Exchange Symbol: RVX
CALGARY, Nov. 9, 2015 /PRNewswire/ - Resverlogix Corp. (TSX:RVX, the Company) today announced the presentation of important new data detailing the actions of apabetalone (RVX-208) in cardiovascular disease (CVD) and chronic kidney disease (CKD) patients at the American Society of Nephrology (ASN) Kidney Week conference in San Diego, CA, USA. The data was summarized in two poster presentations. The first was entitled ‘Apabetalone, a First-in-Class Epigenetic BET-Inhibitor, has Effects on Alkaline Phosphatase (ALP) and Estimated Glomerular Filtration Rate (eGFR) in Subjects with CVD and CKD; a Post-hoc Analysis of the ASSERT, SUSTAIN and ASSURE Clinical Trials’. The data contained in this presentation showed that in patients with a baseline eGFR<60 mL/min/1.73 m2, treatment with RVX-208 for 12-26 weeks lead to an improvement in eGFR and a significant reduction in ALP (p<0.01). In the second presentation entitled ‘Alkaline Phosphatase Lowering by Selective BET inhibition, a Novel Mechanism for Major Adverse Cardiac Events (MACE) Reduction in High Risk CVD, Diabetes and CKD Patients, a Post-hoc Analysis of Phase 2b Studies with Apabetalone’. This presentation contained data gathered in the SUSTAIN and ASSURE trials showing that baseline ALP levels were significantly higher in all patients who suffered from MACE versus those who were free from MACE. One of the most significant findings was in apabetalone treated patients (n=331). In this treated population, patients who suffered from MACE had an increase of ALP by 3 IU/L vs. baseline, while in the event free patients (n=313) ALP decreased by 8 IU/L. This absolute difference of 11 IU/L between these two groups was significant (p=0.02).
In addition to the Company’s presentations listed above, Dr. Kam Kalantar-Zadeh, Professor and Chief, Division of Nephrology and Hypertension at University of California Irvine, highlighted some of the above findings during an oral presentation titled, “Clinical Practice Session: Hot Topics in CKDMBD: Where Do We Stand in 2015 in Management of Bones and Minerals.” Dr. Kalantar-Zadeh’s presentation focused on the importance of ALP as a prognostic biomarker in CVD and CKD patients. The Company continues to review these and additional findings for potential peer reviewed journal publications.
About American Society of Nephrology Kidney Week Conference
ASN Kidney Week is the world’s premier nephrology conference with more than 13,000 kidney professionals from across the globe in attendance. It provides participants exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer’s disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Resverlogix’s Phase 3 clinical trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL) has now commenced. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.
We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to the Company’s Phase 3 clinical trial and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, Alzheimer’s disease, Orphan diseases, and peripheral artery disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com
Kenneth Lebioda
Senior Vice President Business & Corporate Development
Resverlogix Corp.
Phone: 403-254-9252
Email: ken@resverlogix.com
Sarah Zapotichny
Director of Investor Relations & Corporate Communications
Resverlogix Corp.
Phone : 403-254-9252
Email: sarah@resverlogix.com
SOURCE Resverlogix Corp.
Help employers find you! Check out all the jobs and post your resume.
